Status:
COMPLETED
Treatment of Upper Extremity Deep-Vein Thrombosis
Lead Sponsor:
University of Oklahoma
Collaborating Sponsors:
Pfizer
Conditions:
Deep-Vein Thrombosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) f...
Detailed Description
Upper extremity deep-vein thrombosis (DVT) is an increasingly common clinical problem and has been found to cause important pulmonary embolism in up to 36% of cases including fatal embolism. The major...
Eligibility Criteria
Inclusion
- Patients with confirmed upper extremity DVT diagnosed by ultrasound imaging or venogram
Exclusion
- Active, clinically significant bleeding
- Known hypersensitivity to heparin or low-molecular weight heparin
- Currently pregnant or less than 1 week post-partum
- Acquired bleeding diathesis
- Known inherited bleeding disorder
- Renal failure
- Extremes of weight
- Poor performance status
- Unable to return for repeat diagnostic testing or follow-up visits
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT00245856
Start Date
September 1 2002
End Date
December 1 2011
Last Update
February 21 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Veterans Affairs Medical Center
Oklahoma City, Oklahoma, United States, 73104
2
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma, United States, 73117